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Background: The objective of the study was to determine if aspirin use is associated with a reduction in cardiovascular events among “high risk” 
hypertensive patients with chronic stable coronary artery disease (CAD).
methods: Observational analysis was conducted from the INternational VErapamil-SR/Trandolapril STudy database. Participants were enrolled at 
international ambulatory care clinics and were at least 50 years of age with clinically stable CAD. Aspirin use (any dose) was updated at each clinic 
visit and considered as a time-varying covariate in a Cox regression analysis.
results: Slightly more than half of participants reported aspirin use at baseline, which increased to 70% by the last visit. Over 90% of participants 
reported aspirin use during at least one clinic visit. Among participants with a prior ischemic event (myocardial infarction, unstable angina, stroke, or 
transient ischemic attack; n = 9,485) aspirin use was associated with a reduction in all-cause mortality, myocardial infarction, or stroke at a mean 
of 2.7 years; HR = 0.87, 95% CI (0.77 - 0.99), p = 0.03. Among those with no prior ischemic event (n = 13,091) aspirin use was not associated with 
a reduction in these events; HR = 1.11, 95% CI (0.97 - 1.28), p = 0.13. Other outcomes are provided in the table.
conclusions: Among hypertensive CAD patients, aspirin use after an ischemic event is associated with reduced risk; however, among similar 
patients without a prior event, aspirin is not associated with a reduction in risk.
Table. Association of time-varying aspirin use and cardiovascular outcomes
No prior ischemic event (n=13,091) Outcome Events (%) Rate per 1000 pt-yr HR 95% CI P value
All-cause death, MI or stroke 980 (7.5%) 28.1 1.11 0.97-1.28 0.13
All-cause death, MI, stroke, or bleeding 1040 (7.9%) 29.9 1.12 0.98-1.28 0.10
CV death, MI, or stroke 597 (4.6%) 17.1 1.18 0.99-1.43 0.06
All-cause mortality 775 (5.9%) 22.0 0.97 0.83-1.14 0.74
CV mortality 382 (2.9%) 10.9 0.97 0.77-1.21 0.76
Nonfatal MI 125 (1.0%) 3.6 1.23 0.81-1.86 0.34
Nonfatal stroke 102 (0.8%) 2.9 1.86 1.22-2.83 0.0039
Prior Ischemic event
(n = 9,485)
All-cause death, MI or stroke 1289 (13.6%) 49.3 0.87 0.77-0.99 0.03
All-cause death, MI, stroke, or bleeding 1377 (14.5%) 53.0 0.88 0.78-0.99 0.039
CV death, MI, or stroke 808 (8.5%) 30.9 1.04 0.88-1.23 0.65
All-cause mortality 991 (10.5%) 37.1 0.79 0.68-0.91 0.0011
CV mortality 480 (5.1%) 18.0 0.96 0.78-1.19 0.74
Nonfatal MI 179 (1.9%) 6.8 1.26 0.88-1.81 0.21
Nonfatal stroke 177 (1.9%) 6.7 1.05 0.75-1.48 0.77
CV = cardiovascular, HR = hazard ratio, MI = myocardial infarction
